## Simon Kennedy

## List of Publications by Citations

Source: https://exaly.com/author-pdf/7606186/simon-kennedy-publications-by-citations.pdf

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

454 12 21 21 h-index g-index citations papers 551 3.47 24 5.5 L-index avg, IF ext. citations ext. papers

#	Paper	IF	Citations
21	Canagliflozin inhibits interleukin-1Estimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms. <i>Scientific Reports</i> , <b>2018</b> , 8, 5276	4.9	111
20	Reducing In-Stent Restenosis: Therapeutic Manipulation of miRNA in Vascular Remodeling and Inflammation. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 65, 2314-27	15.1	77
19	High Fat Diet Attenuates the Anticontractile Activity of Aortic PVAT via a Mechanism Involving AMPK and Reduced Adiponectin Secretion. <i>Frontiers in Physiology</i> , <b>2018</b> , 9, 51	4.6	39
18	Targeting sphingosine-1-phosphate signalling for cardioprotection. <i>Current Opinion in Pharmacology</i> , <b>2009</b> , 9, 194-201	5.1	34
17	Effect of the sphingosine kinase 1 selective inhibitor, PF-543 on arterial and cardiac remodelling in a hypoxic model of pulmonary arterial hypertension. <i>Cellular Signalling</i> , <b>2016</b> , 28, 946-55	4.9	29
16	Combining mathematical modelling with in vitro experiments to predict in vivo drug-eluting stent performance. <i>Journal of Controlled Release</i> , <b>2019</b> , 303, 151-161	11.7	21
15	Differential effects of chlorinated and oxidized phospholipids in vascular tissue: implications for neointima formation. <i>Clinical Science</i> , <b>2015</b> , 128, 579-92	6.5	18
14	Soluble receptor for advanced glycation end products (sRAGE) attenuates haemodynamic changes to chronic hypoxia in the mouse. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2014</b> , 29, 7-14	3.5	18
13	Mast cells and vascular diseases. <i>Pharmacology &amp; Therapeutics</i> , <b>2013</b> , 138, 53-65	13.9	18
12	Deletion of AMPKI attenuates the anticontractile effect of perivascular adipose tissue (PVAT) and reduces adiponectin release. <i>British Journal of Pharmacology</i> , <b>2017</b> , 174, 3398-3410	8.6	17
11	Altered vascular smooth muscle function in the ApoE knockout mouse during the progression of atherosclerosis. <i>Atherosclerosis</i> , <b>2014</b> , 234, 154-61	3.1	15
10	AMP-activated protein kinase complexes containing the 2 regulatory subunit are up-regulated during and contribute to adipogenesis. <i>Biochemical Journal</i> , <b>2019</b> , 476, 1725-1740	3.8	12
9	The relationship between oxidised LDL, endothelial progenitor cells and coronary endothelial function in patients with CHD. <i>Open Heart</i> , <b>2016</b> , 3, e000342	3	11
8	The hypotensive effect of acute and chronic AMP-activated protein kinase activation in normal and hyperlipidemic mice. <i>Vascular Pharmacology</i> , <b>2015</b> , 74, 93-102	5.9	6
7	PEA-15 (Phosphoprotein Enriched in Astrocytes 15) Is a Protective Mediator in the Vasculature and Is Regulated During Neointimal Hyperplasia. <i>Journal of the American Heart Association</i> , <b>2017</b> , 6,	6	6
6	Perivascular mast cells regulate vein graft neointimal formation and remodeling. <i>PeerJ</i> , <b>2015</b> , 3, e1192	3.1	6
5	An investigation of the antiplatelet effects of succinobucol (AGI-1067). Platelets, <b>2017</b> , 28, 295-300	3.6	4

## LIST OF PUBLICATIONS

4	Short Periods of Hypoxia Upregulate Sphingosine Kinase 1 and Increase Vasodilation of Arteries to Sphingosine 1-Phosphate (S1P) via S1P. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2019</b> , 371, 63-74	4.7	4
3	Do we really understand how drug eluted from stents modulates arterial healing?. <i>International Journal of Pharmaceutics</i> , <b>2021</b> , 601, 120575	6.5	3
2	Requirement for sphingosine kinase 1 in mediating phase 1 of the hypotensive response to anandamide in the anaesthetised mouse. <i>European Journal of Pharmacology</i> , <b>2019</b> , 842, 1-9	5.3	2
1	Nitric oxide generation by NO donors is enhanced following balloon injury in the porcine coronary artery. <i>Endothelium: Journal of Endothelial Cell Research</i> , <b>2007</b> , 14, 105-13		1